Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Nano Biomedicine and Engineering is Scopus-indexed (Q2, CiteScore 7.7), DOAJ. Published by KeAi Communications Co..
Checked against the index lists dated .
ISSN 2150-5578Verify ISSN ↗
Publisher: KeAi Communications Co.
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Biomedical Engineering | 91 / 342 | 73rd | Q2 |
Not listed in: Web of Science, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2009–present, best quartile Q2, CiteScore 7.7.
Nano Biomedicine and Engineering is Q2 in Biomedical Engineering (rank 91 of 342), by CiteScore 2025.
Nano Biomedicine and Engineering is not in the Web of Science Core Collection (SCIE, SSCI, AHCI or ESCI), so Clarivate publishes no Journal Impact Factor for it. Its Scopus CiteScore is 7.7, quartile Q2, 73rd percentile. Any "impact factor" quoted elsewhere is not the Clarivate metric. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.022, quartile Q1, with an H-index of 35.
Nano Biomedicine and Engineering is published by KeAi Communications Co. Its ISSN is 2150-5578.
No — it is not currently in the Web of Science core collections (SCIE, SSCI, AHCI or ESCI).
Yes — it is an open-access journal, listed in DOAJ.
Nano Biomedicine and Engineering has an h-index of 37 and a 2-year mean of 8.16 citations per paper (OpenAlex). Its Scopus CiteScore is 7.7, quartile Q2. On 2-year citations it ranks #30 of 322 Scopus journals in Biomedical Engineering.
Nano Biomedicine and Engineering published 32 papers in 2025; its busiest recent year was 2024 with 57. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 93 research articles (2024–2026), authors are most often from China (59.4%), India (17.6%) and Pakistan (4.9%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.